Canada vs Mauritania: Share of the population living with HIV receiving antiretroviral therapy
Canada
76.2%
in 2022
Mauritania
75.8%
in 2024
Canada rank
62nd
Mauritania rank
64th
Share of the population living with HIV receiving antiretroviral therapy over time
- Canada
- Mauritania
How they compare
Canada currently reports 76.2% against 75.8% in Mauritania, a difference of 0.4%.
The two have swapped places 1 time across 33 shared years of data; in 1990 it was Mauritania ahead.
Canada ranks 62nd and Mauritania ranks 64th of 149 countries.
Canada has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Canada | Mauritania | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 4.0% | 0.0% | 4.0% | Canada |
| 2000s | 30.6% | 4.1% | 26.5% | Canada |
| 2010s | 64.2% | 31.9% | 32.3% | Canada |
| 2020s | 77.4% | 58.4% | 19.1% | Canada |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Canada or Mauritania?
- Canada, at 76.2% against 75.8% in Mauritania as of 2022.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Canada and Mauritania?
- 0.4%, with Canada ahead.
- How many years of comparable data are there for Canada and Mauritania?
- 33 years are reported by both, from 1990 to 2022.
- How do Canada and Mauritania rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Canada ranks 62nd and Mauritania ranks 64th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.